Industry News
Biotechnology Industry News
Roche has set its sights on…
Roche has set its sights on becoming a “top three” obesity company, according to the pharma’s long-awaited strategy for cracking the weight loss market.
Roche has reported a phase 3 win…
Roche has reported a phase 3 win for its oral selective estrogen receptor degrader, bouncing back from an earlier setback to deliver data that could support filings for approval in breast cancer.
Genfit has stopped development of…
Genfit has stopped development of VS-01 in acute-on-chronic liver failure after a patient suffered a serious adverse event in a phase 2 trial.
Sanofi’s long and winding path…
Sanofi’s long and winding path to get its investigational multiple sclerosis drug over the regulatory finish line has taken another turn with the FDA's move to delay its approval decision on the candidate by three
It’s been less than two years…
It’s been less than two years since Roche dove into the obesity space with its $2.7 billion acquisition of Carmot Therapeutics—but a lot has changed since then.
The German drug developer has…
The German drug developer has tapped four industry leaders to take up spots in its C-suite, a move that has prompted three other executives to leave the company.
Renowned biotech veteran Robert…
Renowned biotech veteran Robert Langer is the executive chair of T.Rx Capital, a VC co-founded by his son Michael Langer and aiming to back "visionary founders" at the intersection of technology and biology.
After Carisma Therapeutics laid…
After Carisma Therapeutics laid off 95% of its team earlier this year, a Hail Mary merger proposal with another biotech has fallen through.
Biogen has given Alcyone…
Biogen has given Alcyone Therapeutics a starring role in its drug delivery strategy, paying $85 million to buy the biotech and take control of an implant for getting medicines into the spinal canal.
VectorY Therapeutics has seen the…
VectorY Therapeutics has seen the shape of things to come—and it involves finding fresh ways to deliver its gene therapies into the brain.
Having already stripped back their…
Having already stripped back their development plans for the estrogen receptor (ER) degrader vepdegestrant on the back of mixed data, Pfizer and Arvinas have decided to wash their hands of the drug.
Roche dived into the metabolic…
Roche dived into the metabolic dysfunction-associated steatohepatitis space by agreeing to hand over up to $3.5 billion for 89bio and its phase-3-stage candidate.
Beijing QL Biopharmaceutical has…
Beijing QL Biopharmaceutical has shared phase 2 data on its once-monthly GLP-1 candidate, providing early evidence that the ultra-long-acting prospect can match the efficacy of weekly products from Eli Lilly and Novo Nordisk.
One of the top fundraisers of 2024…
One of the top fundraisers of 2024 is halving its workforce about a year after bringing in a $325 million series C. Cell therapy biotech Arsenal Biosciences will lay off 50% of its staff as
Getting a biotech deal done in…
Getting a biotech deal done in 2025 requires more than good science. It’s about the credibility of your story.
California VC firm Aditum Bio is…
California VC firm Aditum Bio is at it again, this time partnering up with China-based Mabwell Bioscience to launch a new biotech focused on cardiovascular disease.
After being touted as a potential…
After being touted as a potential rival to Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu for months, Johnson & Johnson’s IL-23 drug looks like it has a real shot at taking the crown.
Regeneron is racing to regulators…
Regeneron is racing to regulators after reporting a phase 3 win in an ultrarare disease. The biotech plans to file for FDA approval of garetosmab in fibrodysplasia ossificans progressiva by the end of 2025 on
At this year’s meeting of the…
At this year’s meeting of the European Association for the Study of Diabetes in Vienna, Eli Lilly bolstered the case for its oral GLP-1 orforglipron, showing that its pill can both stand on its own
A phase 3 trial of Priovant…
A phase 3 trial of Priovant Therapeutics’ inflammatory disease prospect brepocitinib has hit its primary endpoint, setting the Roivant-backed biotech up to seek FDA approval for the TYK2/JAK1 inhibitor next year.